Food for Thought ...

The US Federal Tox21 Program: A Strategic and Operational Plan for Continued Leadership

Russell S. Thomas¹, Richard S. Paules², Anton Simeonov³, Suzanne C. Fitzpatrick⁴,
Kevin M. Crofton¹, Warren M. Casey⁵ and Donna L. Mendrick⁶

¹National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA; ²Division of the National Toxicology Program, National Institute of Environmental Health Sciences, NIH, Durham, NC, USA; ³National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA; ⁴US Food and Drug Administration, Silver Spring, MD, USA; ⁵National Toxicology Program, Interagency Center for the Evaluation of Alternative Toxicological Methods, Research Triangle Park, NC, USA; ⁶National Center for Toxicological Research, Food and Drug Administration, Silver Spring, MD, USA

Summary

The traditional approaches to toxicity testing have posed multiple challenges for evaluating the safety of commercial chemicals, pesticides, food additives/contaminants, and medical products. The challenges include the numbers of chemicals that need to be tested, time and resource intensive nature of traditional toxicity tests, and unexpected adverse effects that occur in pharmaceutical clinical trials despite the extensive toxicological testing. Over a decade ago, the U.S. Environmental Protection Agency (EPA), National Toxicology Program (NTP), National Center for Advancing Translational Sciences (NCATS), and the Food and Drug Administration (FDA) formed a federal consortium for "Toxicology in the 21st Century" (Tox21) with a focus on developing and evaluating *in vitro* high-throughput screening (HTS) methods for hazard identification and providing mechanistic insights. The Tox21 consortium generated data on thousands of pharmaceuticals and data poor chemicals, developed better understanding of the limits and applications of *in vitro* methods, and enabled incorporation of HTS data into regulatory decisions. To more broadly address the challenges in toxicology, Tox21 has developed a new strategic and operational plan that expands the focus of its research activities. The new focus areas include developing an expanded portfolio of alternative test systems, addressing technical limitations of *in vitro* test systems, curating legacy *in vivo* toxicity testing data, establishing scientific confidence in the *in vitro* test systems, and refining alternative methods for characterizing pharmacokinetics and *in vitro* assay disposition. The new Tox21 strategic and operational plan addresses key challenges to advance toxicology testing and will benefit both the organizations involved and the toxicology community.

Keywords: Tox21, alternative methods, high-throughput screening, validation, pharmacokinetics

1 Background

The traditional approaches to toxicity testing have posed multiple challenges for evaluating the safety of industrial and environmental chemicals, pesticides, food additives, food contaminants, and medical products. There are tens of thousands of chemicals used across all sectors of the economy and there

are many more present as contaminants in the environment and food supply. In addition, humans are rarely exposed to a single chemical, resulting in an incalculable number of chemical combinations to evaluate for potential human health concerns. Apart from specific classes such as pesticides and medical products, most chemicals have undergone limited, if any, traditional toxicity testing leading to a lack of adequate information to

Disclaimer: This article does not necessarily reflect the policy of the US Environmental Protection Agency, National Toxicology Program, National Institutes of Health, or Food and Drug Administration.

Received March 1, 2018;
Epub March 8, 2018;
doi:10.14573/altex.1803011

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International license (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited.

assess human health risks (NRC, 1984). The testing of such a large number of chemicals and mixture combinations across a comprehensive array of traditional animal-based tests raises significant ethical and resource issues. For medical products, substantial preclinical safety data is collected and used to evaluate potential human health concerns. However, despite the amount of safety data, unexpected adverse effects can still be observed in clinical trials or post-approval, suggesting that gaps remain in our understanding of human responses and the traditional toxicological endpoints measured in preclinical studies.

In response to the challenges associated with the traditional toxicity testing paradigm, the National Research Council (NRC) produced the report entitled “Toxicity Testing in the 21st Century: A Vision and A Strategy” (NRC, 2007). This report recommended a fundamental shift from the traditional animal-based toxicity testing paradigm that relies on clinical and histopathological observations towards a predictive toxicology approach that relies on disruption of molecular events and cellular pathways identified using human-relevant *in vitro* assays and computational modeling. Based on the recommendations in this report, a joint effort was initiated through a Memorandum Of Understanding (MOU) executed by the U.S. Environmental Protection Agency (EPA)/Office of Research and Development/National Center for Computational Toxicology (NCCT), National Institutes of Health (NIH)/National Institute of Environmental Health Sciences/National Toxicology Program (NTP), and the NIH/National Chemical Genomics Center (NCGC), previously a part of the National Human Genome Research Institute and now a part of the National Center for Advancing Translational Sciences (NCATS) (Collins et al., 2008; Kavlock et al., 2009). This collaboration, informally called Tox21, was formed to address the goals of: (1) identifying mechanisms of chemically induced biological activity; (2) prioritizing chemicals for more extensive toxicological evaluation; and (3) developing more predictive models of *in vivo* biological response. In 2010, this MOU was expanded to include the US Food and Drug Administration (FDA). In 2015, the Tox21 collaborators renewed their commitment to the program through a third five-year MOU between NTP, NCATS, EPA, and FDA. A collaboration of this type and duration is unique within the federal government.

2 Initial successes of Tox21

Since its inception, Tox21 has been a productive interagency collaboration. It has advanced chemical testing by generating over 120 million data points on about 8500 chemicals using *in vitro* high throughput screening (HTS) assays (Tice et al., 2013). The combination of Tox21 and ToxCast data currently represents the largest generation of *in vitro* bioassay data for environmental chemicals (Richard et al., 2016; Tice et al., 2013). A large number of environmental chemicals tested in the Tox21 collaboration had little empirical data relevant to biological tar-

gets or possible adverse outcomes. The Tox21 data have been publicly released via multiple agency websites, highlighting the transparency associated with the Tox21 collaboration. Furthermore, the Tox21 partners have instituted a timely delivery of the data into the public domain, with only a minimal holding period to allow for preparation of a manuscript describing the general findings from a particular screen. The publicly available data have been used by national and international scientists and organizations for a broad range of purposes. For example, academic scientists have used Tox21 data to rank chemicals of concern at Superfund sites (Tilley et al., 2017) and the International Agency for Research on Cancer has used Tox21 data to help inform cancer hazard evaluations (Chiu et al., 2018).

The Tox21 collaboration has resulted in the publication of over 200 scientific peer-reviewed articles in approximately 56 journals and these publications have been cited in more than 140 policy-related documents and expert panel reports including 80 reports by the U.S. National Academy of Sciences¹. The Tox21 data coupled with computational models and additional data from the EPA's ToxCast program and reference chemical curation by the National Toxicology Program, are enabling high-throughput screening assays to be used for regulatory decisions in the EPA's Endocrine Disruptor Screening Program to both prioritize chemicals for further testing and to replace some Tier 1 screening assays (Browne et al., 2015; EPA, 2015). The application of Tox21 data to regulatory decisions has also been supported in a follow-up report released by the NRC entitled “Using 21st Century Science to Improve Risk-Related Evaluations” (NRC, 2017).

3 Lessons learned

Part of the success of Tox21 includes a better understanding of the challenges that remain on the path to achieving the goals of the original 2007 NRC report. These challenges include technological and biological barriers associated with the current methods, as well as barriers in more efficiently translating the results into regulatory decisions. The technological and biological barriers include a lack of physiologically-relevant metabolic competence for many of the assays, the testing of only DMSO soluble chemicals, limited coverage of important cellular and intracellular processes, limited duration exposures, and the estimation of potency based on nominal chemical concentrations (Tice et al., 2013).

Additional barriers in translating the results from the Tox21 data into regulatory decisions and acceptance by the general toxicology community include insufficient communication, training, and education. The large amount of data, and technical complexity of the HTS data pose many barriers to understanding and accepting the data. In addition, translating the results from Tox21 data into decisions by regulators will require a pragmatic path forward for establishing scientific confidence in the *in vitro* assays and a better understanding of the qualitative and

¹ <https://www.altmetric.com/explorer/report/17875d15-d738-46ca-8fe0-51e42322e6e4>; last accessed August 2017

quantitative differences in uncertainty between the traditional methods and the new approaches.

4 Changes in focus

The original focus of Tox21 was to develop and apply *in vitro* HTS methods for hazard identification and provide mechanistic insights into the perturbed pathways. To solve the challenges involved in efficiently and economically evaluating the safety of chemicals, develop more human-relevant test systems, better understand the mechanisms and pathways of toxicity, and more broadly achieve the goals laid out in the 2007 NRC report, Tox21 has developed a new strategic and operational plan that begins with expanding the focus of its research activities. The new activities are targeted to address key challenges in advancing toxicology testing in the 21st century, and if successful, will have substantial benefit to each organization regardless of differences in their unique missions. These new areas of focus are outlined briefly below.

4.1 Area of focus 1: Develop alternative test systems that are predictive of human toxicity and dose response

The overall aim of toxicity testing is identifying all the potential hazards that a chemical can elicit in an organism and characterizing the dose-response relationships for those hazards. New technologies and testing platforms are needed in Tox21 that more comprehensively capture the potential toxicological effects of chemicals, allow translation of molecular and pathway perturbations to effects at the tissue-, organ-, and organism-level, and capture potential population variability in toxicodynamic responses. To more comprehensively capture potential toxicological effects, the Tox21 consortium will develop and characterize new technologies that provide multiplexed read-outs of chemically-induced changes in the global transcriptome. This work will include, for example, the use of targeted and/or global gene expression methods that allow for the analyses of thousands of genes directly from cell lysates. At the same time, the existing quantitative HTS efforts will be focused on developing assays for molecular events in high priority adverse outcome pathways (AOPs) and expanding technological capabilities to include previously inaccessible signal types (e.g., fast transient cellular changes such as ion channel signaling), high-content microscopy (e.g., micronucleus or staining for organelles or particular cellular proteins), and two-photon imaging of 3D cellular organoid structures.

Changes at the molecular and pathway level are often difficult to interpret with regards to their potential effects at the tissue-, organ, and organism-level. To date, Tox21 has used biologically simplistic test methods (e.g., receptors, stable reporter-expressing cell lines) that do not include primary tissue-specific cell context and many of the complex cell-to-cell interaction or feedback systems that exist at higher levels of bi-

ological organization. New alternative test systems are needed that incorporate the complexities found at these higher levels to augment the simpler HTS assays employed to date. To achieve this, the Tox21 consortium will leverage alternative species such as *Danio rerio* (zebrafish) (Padilla et al., 2012; Truong et al., 2014), as well as recent advances in organotypic culture models, microscale tissues, and microphysiological systems (Bhatia and Ingber, 2014; Low and Tagle, 2017). It is recognized that such approaches may have much lower throughput than current Tox21 assays and thus, for testing thousands of compounds, these technologies will be used in a tiered, follow-up capacity to bridge between the molecular perturbations identified in the high-throughput assays and the tissue-, organ-, and organism-level phenotypic outcomes.

Translation of toxicity testing into risk assessment requires an understanding of population variability and identification of potentially susceptible populations. Most of the HTS assays employed in Tox21 do not capture potential population variability in toxicodynamic response. Efforts by members of the Tox21 collaboration and partners have begun to address this challenge (Abdo et al., 2015; Eduati et al., 2015; O'Shea et al., 2011). The Tox21 consortium will expand on previous efforts and work to develop and integrate induced pluripotent stem cell (iPSC) technology into the new alternative test systems and high-throughput screening platforms to incorporate variability in chemical responses from genetically diverse populations.

4.2 Area of focus 2: Address key technical limitations of current *in vitro* test systems

As mentioned above, there are technical limitations to the current *in vitro* test systems. Some of these limitations are listed among the lessons learned in this article (see above). The Tox21 consortium will work to adapt existing methods or to develop new methods that will allow the consortium to systematically address the main technical challenges that face *in vitro* test systems. For example, the Tox21 partners have already begun to identify potential solutions to the metabolic competence limitation through both in-house efforts and using a global science crowd-sourcing initiative² (DeGroot et al., 2018; Ramaiahgari et al., 2017).

4.3 Area of focus 3: Curate and characterize legacy *in vivo* toxicity studies

The toxicological community as well as the organizations involved in Tox21 have data from legacy *in vivo* toxicity studies. These data form the basis for how we currently understand the potential effects of chemicals and provide a rich resource with which to help interpret the *in vitro* test systems and link the effects observed at the molecular level to those observed at the tissue-, organ-, and organism-level. The data will also be useful for characterizing the qualitative and quantitative variability associated with traditional *in vivo* toxicity studies in order to understand how they may differ from the new *in vitro* testing approaches (Browne, et al., 2015; Hoffmann et al., 2010;

² <https://factor.niehs.nih.gov/2016/2/science-highlights/challenge/index.htm>

Kleinstreuer et al., 2015). The interagency Tox21 consortium will work together to identify and curate these legacy, non-proprietary toxicity studies, enter data into a computable form, and harmonize ontologies used to characterize the toxicity studies.

4.4 Area of focus 4: Establishing scientific confidence in *in vitro* test systems and integrated assay batteries

A standard approach for the validation of *in vitro* test systems for hazard identification (e.g., OECD, 2005) has been used by U.S. Federal agencies and international organizations over the past decade. However, this approach has proven to be largely unsustainable; taking many years to complete, requiring significant resources, and typically focusing on a one-for-one replacement of a specific regulatory endpoint of interest (Griesinger et al., 2016; Judson et al., 2013). Although regulatory agencies are open to using new methods and integrated assay batteries such as the Tox21 HTS assays, for a range of decision contexts, the agencies must have confidence that the new approaches provide data that are reliable, reproducible, and relevant to the intended context of use. A new area of focus for Tox21 is to perform research that informs the development of an evaluation framework for the definition of performance standards which can be used to establish confidence in the new approaches. The underlying research will need to support a framework that is generalizable and scalable for key events and pathways that range from data-rich (e.g., estrogen receptor) to data-poor.

4.5 Area of focus 5: Refine and deploy *in vitro* methods for characterizing pharmacokinetics and *in vitro* disposition

Current approaches to extrapolating estimates of *in vitro* potency to external doses assume that the nominal concentrations

used in the *in vitro* assays are equivalent to plasma concentrations and that the *in vitro* toxicokinetic assays and the *in vitro*-to-*in vivo* extrapolation (IVIVE) modeling sufficiently capture the complex toxicokinetic behaviors of industrial and environmental chemicals as well as pesticides and pharmaceuticals. However, it has been well established that active and passive disposition of chemicals in *in vitro* assays (e.g., binding to plastic, transport inside or outside the cell, binding to media proteins) may significantly bias potency estimates for some chemicals (Blaauboer, 2010). In addition, the *in vitro* toxicokinetic assays and IVIVE modeling approaches do not work well for certain chemicals or chemical classes when compared with traditional *in vivo* pharmacokinetic studies (Wambaugh et al., 2015). To overcome these challenges and to advance the utilization of Tox21 data, a new area of focus for Tox21 will be on new methods and computational modeling approaches that better predict the relationship between target tissue concentrations and external doses of chemicals. In addition, the Tox21 consortium will begin to collect the experimental and computational data necessary to incorporate *in vitro* disposition into estimates of effective potency and efficacy.

5 Changes in structure

To accommodate the new strategic direction and the expansion in focus of the Tox21 collaboration, a greater integration among Tox21 partners is required. This presents multiple challenges as each partner has different organizational and programmatic drivers. To overcome this issue, a new structure has been implemented for Tox21 (Fig. 1). The central functional group in the new structure is the cross-partner project. Cross-partner projects are defined research activities that fall into one of the five areas

Fig. 1: New Tox21 organizational structure

The central functional group is the cross-partner project. The cross-partner projects are overseen by the Tox21 management team and supported by infrastructure teams that are tasked with maintaining specific activities central to most of the research projects.

Tab. 1: Initial Cross-Partner Projects and Infrastructure Teams for Tox21

Cross-Partner Projects	Infrastructure Teams
<i>In Vitro</i> Disposition of Tox21 Chemicals	Chemical Library Management
Developing Performance Based Standards for Tox21 Assays	Communications
Development of a Reference Chemical Dataset for Interpretation of High-Throughput Transcriptomic Screening Data	Assay Evaluation and Screening
Incorporating Genetic Susceptibility into Developmental Neurotoxicity Screening	
Development of a High-Throughput Assay to Identify 5- α Reductase Inhibitors for Orthogonal Evaluation in an Androgen-dependent Human 3D Prostate Tissue	
Cell Line Selection for High-Throughput Transcriptomic Screening	
Predictive Modeling of Developmental Toxicity with Human Pluripotent Stem Cells	
Development of a High-Throughput Assay to Identify Acetylcholinesterase Inhibitors	

of focus and must have project support from two or more Tox21 partners. The cross-partner projects have three-year terms and are reviewed annually by the Tox21 leadership enabling a more formal research planning and execution process. The cross-partner projects are supported by infrastructure teams that are tasked with maintaining specific activities that are central to most of the research projects. The initial infrastructure teams and cross-partner projects are listed in Table 1. Public abstracts are available on the Tox21 website³.

6 Conclusion

The Tox21 collaboration has provided both the data and the science to begin implementation of the National Research Council's vision of toxicity testing in the 21st century (NRC, 2007). Since its inception, the Tox21 program has led the world in the development and use of high-throughput screening assays and has provided publicly accessible data for the biological activity of ~8500 chemicals (Kavlock et al., 2012; Tice et al., 2013). These data have provided a foundation on which a pivot in chemical hazard identification and *in vitro* dose-response assessment is now beginning to influence the fields of toxicology and risk assessment worldwide (Chiu, et al., 2018; EPA, 2014). It is time to expand the focus of the Tox21 consortium to include other data and methods necessary to fully advance toxicity testing into the 21st century.

References

- Abdo, N., Xia, M., Brown, C. C. et al. (2015). Population-based *in vitro* hazard and concentration-response assessment of chemicals: The 1000 genomes high-throughput screening study. *Environ Health Perspect* 123, 458-466. doi:10.1289/ehp.1408775
- Bhatia, S. N. and Ingber, D. E. (2014). Microfluidic organs-on-chips. *Nat Biotechnol* 32, 760-772. doi:10.1038/nbt.2989
- Blaauboer, B. J. (2010). Biokinetic modeling and *in vitro-in vivo* extrapolations. *J Toxicol Environ Health B Crit Rev* 13, 242-252. doi:10.1080/10937404.2010.483940
- Browne, P., Judson, R. S., Casey, W. M. et al. (2015). Screening chemicals for estrogen receptor bioactivity using a computational model. *Environ Sci Technol* 49, 8804-8814. doi:10.1021/acs.est.5b02641
- Chiu, W. A., Guyton, K. Z., Martin, M. T. et al. (2018). Use of high-throughput *in vitro* toxicity screening data in cancer hazard evaluations by IARC Monograph Working Groups. *ALTEX* 35, 51-64. doi:10.14573/altex.1703231.
- Collins, F. S., Gray, G. M. and Bucher, J. R. (2008). Toxicology. Transforming environmental health protection. *Science* 319, 906-907. doi:10.1126/science.1154619
- Eduati, F., Mangravite, L. M., Wang, T. et al. (2015). Prediction of human population responses to toxic compounds by a collaborative competition. *Nat Biotechnol* 33, 933-940. doi:10.1038/nbt.3299
- DeGroot, D. E., Swank, A., Thomas, R. S. et al. (2018). mRNA transfection retrofits cell-based assays with xenobiotic metabolism. *J Pharmacol Toxicol Methods*, Epub ahead of print. doi:10.1016/j.vascn.2018.03.002
- EPA (2014). Integrated bioactivity and exposure ranking: A Computational approach for the prioritization and screening of chemicals in the endocrine disruptor screening program. U.S. Environmental Protection Agency, Federal Register. <https://www.regulations.gov/document?D=EPA-HQ-OPP-2014-0614-0003>
- EPA (2015). Use of high throughput assays and computational tools: Endocrine disruptor screening program; Notice of availability and opportunity for comment. US Environmental Protection Agency, Federal Register. <https://www.federalregister.gov/d/2015-15182>

³ <https://www.epa.gov/chemical-research/toxicology-testing-21st-century-tox21>

- Griesinger, C., Desprez, B., Coecke, S. et al. (2016). Validation of alternative in vitro methods to animal testing: Concepts, challenges, processes and tools. *Adv Exp Med Biol* 856, 65-132. doi:10.1007/978-3-319-33826-2_4
- Hoffmann, S., Kinsner-Ovaskainen, A., Prieto, P. et al. (2010). Acute oral toxicity: Variability, reliability, relevance and interspecies comparison of rodent LD50 data from literature surveyed for the ACuteTox project. *Regul Toxicol Pharmacol* 58, 395-407. doi:10.1016/j.yrtph.2010.08.004
- Judson, R., Kavlock, R., Martin, M. et al. (2013). Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. *ALTEX* 30, 51-56. doi:10.14573/altex.2013.1.051
- Kavlock, R. J., Austin, C. P. and Tice, R. R. (2009). Toxicity testing in the 21st century: Implications for human health risk assessment. *Risk Anal* 29, 485-487; discussion 492-497. doi:10.1111/j.1539-6924.2008.01168.x
- Kavlock, R., Chandler, K., Houck, K. et al. (2012). Update on EPA's ToxCast program: Providing high throughput decision support tools for chemical risk management. *Chem Res Toxicol* 25, 1287-1302. doi:10.1021/tx3000939
- Kleinstreuer, N. C., Ceger, P. C., Allen, D. G. et al. (2015). A curated database of rodent uterotrophic bioactivity. *Environ Health Perspect* 124, 556-562. doi:10.1289/ehp.1510183
- Low, L. A. and Tagle, D. A. (2017). Microphysiological systems ("organs-on-chips") for drug efficacy and toxicity testing. *Clin Transl Sci* 10, 237-239. doi:10.1111/cts.12444
- NRC (1984). *Toxicity Testing: Strategies to Determine Needs and Priorities*. Washington, D.C., USA: National Research Council of the National Academies. <http://bit.ly/2FRRPmv>
- NRC (2007). *Toxicity Testing in the 21st Century: A Vision and a Strategy*. Washington, D.C., USA: National Research Council of the National Academies. <http://bit.ly/2Bp48Aq>
- NRC (2017). *Using 21st Century Science to Improve Risk-Related Evaluations*. Washington, D.C., USA: National Research Council of the National Academies. <http://bit.ly/2j9zWAr>
- O'Shea, S. H., Schwarz, J., Kosyk, O. et al. (2011). In vitro screening for population variability in chemical toxicity. *Toxicol Sci* 119, 398-407. doi:10.1093/toxsci/kfq322
- OECD – Organisation for Economic Cooperation and Development (2005). Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment. OECD Series on Testing and Assessment No. 34. <http://bit.ly/24oFedN>
- Padilla, S., Corum, D., Padnos, B. et al. (2012). Zebrafish developmental screening of the ToxCastTM Phase I chemical library. *Reprod Toxicol* 33, 174-187. doi:10.1016/j.reprotox.2011.10.018
- Ramaiahgari, S. C., Waidyanatha, S., Dixon, D. et al. (2017). Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening. *Toxicol Sci* 160, 189-190. doi:10.1093/toxsci/kfx194
- Richard, A. M., Judson, R. S., Houck, K. A. et al. (2016). ToxCast chemical landscape: Paving the road to 21st century toxicology. *Chem Res Toxicol* 29, 1225-1251. doi:10.1021/acs.chemrestox.6b00135
- Tice, R. R., Austin, C. P., Kavlock, R. J. and Bucher, J. R. (2013). Improving the human hazard characterization of chemicals: A Tox21 update. *Environ Health Perspect* 121, 756-765. doi:10.1289/ehp.1205784
- Tilley, S. K., Reif, D. M. and Fry, R. C. (2017). Incorporating ToxCast and Tox21 datasets to rank biological activity of chemicals at Superfund sites in North Carolina. *Environ Int* 101, 19-26. doi:10.1016/j.envint.2016.10.006
- Truong, L., Reif, D. M., St Mary, L. et al. (2014). Multidimensional in vivo hazard assessment using zebrafish. *Toxicol Sci* 137, 212-233. doi:10.1093/toxsci/kft235
- Wambaugh, J. F., Wetmore, B. A., Pearce, R. et al. (2015). Toxicokinetic triage for environmental chemicals. *Toxicol Sci* 147, 55-67. doi:10.1093/toxsci/kfv118

Conflict of interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors of this article would like to thank all the current and former members of the consortium for their work in making the program a success, former leadership of the consortium (Bob Kavlock, Ray Tice, and Chris Austin) for their founding vision and courage in forming the consortium, and members of the toxicology community and general public for supporting the effort.

Correspondence to

Russell Thomas, PhD
National Center for Computational Toxicology
U.S. Environmental Protection Agency
109 TW Alexander Drive, MC D143-02
Research Triangle Park, NC 27711, USA
Phone: +1 919-541-5776
e-mail: Thomas.Russell@epa.gov